Delia De Lisi
Trento, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: June 02, 2026
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Journal: The oncologist
Published: June 13, 2025
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management.
Journal: Journal of neuroendocrinology
Published: June 04, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Journal: Breast (Edinburgh, Scotland)
Published: October 22, 2024
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.
Journal: Journal of clinical medicine
Published: May 09, 2024
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
Journal: Seminars in oncology
Published: May 03, 2023
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Journal: American journal of clinical oncology
Published: February 22, 2021
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Journal: Future oncology (London, England)
Published: July 25, 2019
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Journal: The Prostate
Published: February 27, 2019
Psychosocial Issues in Long-Term Survivors of Testicular Cancer.
Journal: Frontiers in endocrinology
Published: January 08, 2019
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Journal: BMC cancer
Published: September 14, 2018
Last Updated: 09/26/2026